false 0000316253 0000316253 2024-08-13 2024-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 13, 2024

 

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

 

New York   001-09974   13-2866202
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

21 Executive Blvd.

Farmingdale, New York 11735

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (631) 755-5500

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.01 per share   ENZ   The New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01. Other Events.

 

Agreement Reached with Attorneys General of New York, New Jersey and Connecticut

 

On August 13, 2024, the Attorneys General of New York and Connecticut issued press releases announcing that agreements, effective as of August 8, 2024, were entered into between Enzo Biochem, Inc., its subsidiary Enzo Clinical Labs, Inc., the assets of which were sold resulting in the cessation of our clinical services operations (together the “Company”), and the Attorneys General of New York, New Jersey and Connecticut. These agreements, consisting of an Assurance of Discontinuance entered into with the New York Attorney General, a Consent Order, entered into with the New Jersey Attorney General, and an Assurance of Voluntary Compliance, entered into with the Connecticut Attorney General, resolve inquiries previously disclosed in the Company’s public filings related to the ransomware attack it experienced in April 2023. As stated in the terms of these agreements, the Company cooperated with the investigations and neither admits nor denies the investigative findings of the Attorneys General. The Company also agrees to monetary relief in the amount of $4.5 million dollars, which shall, within 45 days, be divided and the apportionment paid directly to each of the Attorneys General at their direction. The agreements further require the Company to implement and maintain certain cybersecurity enhancements, substantially all of which have already been undertaken or are underway, as well as an Information Security Program as described in the agreements, on a going forward basis.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENZO BIOCHEM, INC.
   
  By: /s/ Patricia Eckert
  Name:  Patricia Eckert
  Title: Chief Financial Officer
     
Date: August 14, 2024  

 

 

2

 

 

v3.24.2.u1
Cover
Aug. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 13, 2024
Entity File Number 001-09974
Entity Registrant Name ENZO BIOCHEM, INC.
Entity Central Index Key 0000316253
Entity Tax Identification Number 13-2866202
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 21 Executive Blvd.
Entity Address, City or Town Farmingdale
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11735
City Area Code (631)
Local Phone Number 755-5500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ENZ
Security Exchange Name NYSE
Entity Emerging Growth Company false
Enzo Biochem (NYSE:ENZ)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Enzo Biochem
Enzo Biochem (NYSE:ENZ)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Enzo Biochem